システミックコリネルジック剤は,リチウムで治療されたネズミの脳に発作と脳損傷を引き起こす
Science (New York, N.Y.)
|April 15, 1983
まとめ
ピロカルピンやフィソスティグミンと併用したリチウム治療は,ネズミで辺縁性発作や脳損傷を引き起こした. この神経毒性症候群は,D-myo-inositol-1-phosphateの値上昇によって特徴づけられ,アトロピンによって予防され,精神医学薬の安全性への潜在的な影響を示唆しています.
科学分野:
- 神経科学は神経科学である.
- 薬理学 薬理学とは
- 毒理学 毒理学 毒理学
背景:
- リチウムは,精神科化学療法で広く使用されています.
- ピロカルピンとフィソスティグミンはコリナージックアゴニストです.
- フォスフォノシチドの代謝は,神経の機能にとって極めて重要です.
研究 の 目的:
- コリン活性アゴニストとリチウムの併用による神経毒性の研究.
- リチウム誘発性神経毒性におけるD-ミオイノシトール-1-ホスファートの役割を調査する.
- アトロピンがこの毒性症候群を予防できるかどうかを判断する.
主な方法:
- ネズミはリチウム塩化物,その後ピロカルピンまたはフィソスティグミンで治療された.
- 脳組織と血液のリチウム濃度が分析されました.
- D-myo-inositol-1-phosphateのレベルが測定されました.
- アトロピン投与の効果を評価した.
主要な成果:
- リチウムとピロカルピンまたはフィソスティグミンの併用は,持続的なリンパ性発作と広範な脳損傷を引き起こす.
- D-myo-inositol-1-phosphateの脳濃度の上昇が観察されました.
- アトロピンは,神経毒性症候群の発症を効果的に予防しました.
- フィソスティグミンとリチウムの有効用量は,精神科での治療用量と同等であった.
結論:
- リチウム治療の文脈におけるホルモン過刺激は,重度の神経毒性につながる可能性があります.
- D-myo-inositol-1-phosphateの蓄積は,この毒性のマーカーである可能性があります.
- アトロピンは,このリチウム・コレニン神経毒性症候群に対する保護効果を示しています.
- これらの発見は,精神医学における併用薬物療法に関連する潜在的なリスクを強調しています.
関連する概念動画
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
01:26Anticholinesterase Agents: Poisoning and Treatment
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...
01:24Mania and Antimanic Drugs: Overview
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as a...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:20Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...